MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Zomedica Corp. Retained Earnings 2011-2026 | ZOM
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Zomedica Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -171 M | -136 M | -119 M | - | -52.1 M | -32.3 M | -15.6 M | -158 K | -112 K | -78.7 K | -1.34 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.34 K | -171 M | -52.7 M |
Quarterly Retained Earnings Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -295 M | -289 M | -282 M | -218 M | -211 M | -204 M | - | -171 M | -149 M | -148 M | -143 M | -136 M | -134 M | -129 M | -123 M | -119 M | -116 M | -110 M | -105 M | -69 M | -69 M | -69 M | -69 M | -52.1 M | -52.1 M | -52.1 M | -52.1 M | -32.3 M | -32.3 M | -32.3 M | -32.3 M | -15.6 M | -15.6 M | -15.6 M | -15.6 M | -7.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -7.56 M | -295 M | -108 M |
Retained Earnings of other stocks in the Drug manufacturers industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-457 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-423 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-418 M | - | - | $ 142 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-305 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.15 B | - | - | $ 754 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-794 M | - | - | $ 2.06 B |  France |
 |
Canopy Growth Corporation
CGC
|
-10.9 B | $ 1.19 | 3.48 % | $ 128 M |  Canada |
 |
China Pharma Holdings
CPHI
|
-44 M | $ 0.61 | -1.46 % | $ 10.7 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
-24 M | $ 3.9 | 1.56 % | $ 54.8 M | USA |
 |
Cronos Group
CRON
|
1.06 B | $ 2.74 | 3.6 % | $ 1.43 B | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
112 M | - | -39.89 % | $ 27.7 M | USA |
 |
Catalent
CTLT
|
-781 M | - | - | $ 11.5 B | USA |
 |
Evoke Pharma
EVOK
|
-123 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-1.43 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-659 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
-589 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-21.8 M | $ 10.91 | -0.27 % | $ 559 M | USA |
 |
Harrow Health
HROW
|
-134 M | $ 52.51 | 1.86 % | $ 1.71 B | USA |
 |
Endo International plc
ENDP
|
-15.4 B | - | - | $ 28.9 M |  Irlanda |
 |
Athenex
ATNX
|
-1.02 B | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
-609 M | $ 4.3 | -0.69 % | $ 267 M | USA |
 |
OrganiGram Holdings
OGI
|
-145 M | $ 1.44 | 2.5 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
-596 M | - | 1.15 % | $ 7.11 M | USA |
 |
Jupiter Wellness
JUPW
|
-115 M | - | - | $ 33.6 M | USA |
 |
Bausch Health Companies
BHC
|
-9.78 B | $ 6.04 | 0.83 % | $ 2.2 B | Canada |
 |
Sundial Growers
SNDL
|
-565 M | $ 1.55 | 4.03 % | $ 3.37 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-187 M | - | - | $ 193 M | Canada |
 |
Pacira BioSciences
PCRX
|
-206 M | $ 23.39 | 1.21 % | $ 1.08 B | USA |
 |
Organogenesis Holdings
ORGO
|
-40.1 M | $ 4.01 | 2.42 % | $ 528 M | USA |
 |
PetIQ
PETQ
|
-161 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
-2.25 B | $ 14.63 | 0.48 % | $ 2.01 B | USA |
 |
Aurora Cannabis
ACB
|
-3.59 B | $ 3.8 | 4.11 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
11.8 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-1.37 B | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-279 M | - | -4.76 % | $ 65.3 M | USA |
 |
Rockwell Medical
RMTI
|
-397 M | $ 0.94 | 1.95 % | $ 21.9 M | USA |
 |
Relmada Therapeutics
RLMD
|
-561 M | $ 4.25 | 5.33 % | $ 128 M | USA |
 |
Tilray
TLRY
|
-2.42 B | $ 7.89 | 4.44 % | $ 4.88 B | Canada |
 |
OptiNose
OPTN
|
-720 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
-652 M | $ 12.04 | - | $ 855 M | USA |
 |
PLx Pharma
PLXP
|
-148 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-198 M | $ 2.83 | -0.35 % | $ 3.51 M | USA |
 |
Solid Biosciences
SLDB
|
-783 M | $ 6.17 | 5.11 % | $ 252 M | USA |
 |
SCYNEXIS
SCYX
|
-355 M | $ 0.8 | 3.91 % | $ 38.3 M | USA |
 |
Tricida
TCDA
|
-810 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
-295 M | $ 2.63 | 6.05 % | $ 355 M | USA |
 |
TherapeuticsMD
TXMD
|
-950 M | $ 2.25 | -1.32 % | $ 23.5 M | USA |
 |
cbdMD
YCBD
|
-182 M | $ 0.92 | 0.72 % | $ 3.97 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-275 M | - | - | $ 55.5 M | USA |
 |
Viatris
VTRS
|
5.18 B | $ 16.15 | 1.22 % | $ 19.6 B | USA |